IL-11 is a member of the IL-6 family of cytokines and a mediator of fibrosis. Blocking IL-11 has the potential to be used as a monotherapy or in combination with standard-of-care agents that target other fibroproliferative factors.

The collaboration will focus on idiopathic pulmonary fibrosis, a progressive disease in need of more effective treatments. The collaboration will explore targeting the IL-11 receptor as a potential therapeutic intervention. Lassen has developed a mAb, LASN-01, targeting the IL-11 receptor alpha.

The Cedars Sinai team will be led by Cory Hogaboam, PhD, professor of medicine and a research scientist in the department of medicine at the Women's Guild Lung Institute.

Financial details of the collaboration were not disclosed.

Life Edit receives $400K to find gene editing approaches for cystic fibrosis
Life Edit Therapeutics has received a $400,000 award from the Cystic Fibrosis Foundation to identify potential gene editing approaches to treat patients...

Patient-specific airway stem cells developed to model lung diseases
Researchers have successfully created airway basal stem cells in vitro from induced pluripotent stem cells. These cells can be used to study acquired...

Moderna, Vertex collaborate on gene editing therapies for cystic fibrosis
Moderna and Vertex Pharmaceuticals have entered a three-year research collaboration for the discovery and development of lipid nanoparticles and messenger...